Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;2:177-83.
doi: 10.2147/CPAA.S11795. Epub 2010 Sep 14.

In Vitro Cytotoxicity of Combinations of Dichloroacetate With Anticancer Platinum Compounds

Affiliations
Free PMC article

In Vitro Cytotoxicity of Combinations of Dichloroacetate With Anticancer Platinum Compounds

Ulrike Olszewski et al. Clin Pharmacol. .
Free PMC article

Abstract

Purpose: Dichloroacetate (DCA) inhibits pyruvate dehydrogenase kinase (PDK), and thus promotes glucose oxidation over glycolysis and induces apoptotic death of tumor cells. The present study investigated the potential of DCA to increase the antitumor effects of platinum- based compounds against a panel of permanent cell lines, including small cell lung cancer (SCLC), ovarian cancer, and Ewing's sarcoma in vitro.

Methods: DCA at a concentration of 10 mM was combined with cisplatin, carboplatin, satraplatin, the satraplatin metabolite JM118, oxaliplatin, oxoplatin, and picoplatin, and the cytotoxic activity was evaluated in proliferation tests employing a panel of different cell lines. Additionally, cells were pretreated with DCA and then exposed to the platinum drugs and etoposide, or incubated with cisplatin or etoposide followed by application of DCA, respectively.

Results: DCA 10 mM significantly increased the cytotoxicity of the platinum-based drugs carboplatin, satraplatin, JM118, and oxoplatin, but not cisplatin, picoplatin, and oxaliplatin in vitro. Preincubation of cell lines with DCA 10 mM for three days reduced the antiproliferative activity of platinum-based agents in sequential application, but exposure of cells pretreated with cisplatin or etoposide to DCA resulted in minor sensitization. The inhibitory effect of DCA showed no correlation with sensitization to the platinum compounds.

Conclusion: DCA alone in a concentration that shows low antiproliferative activity is capable of increasing the cytotoxicity of selected platinum compounds upon coincubation, and such combinations may be interesting for clinical application in tumors like SCLC, Ewing's sarcoma, and ovarian cancer refractory to cisplatin chemotherapy as standard care. The mechanism of this synergistic effect of DCA in combination with specific platinum species remains to be investigated.

Keywords: apoptosis; cytotoxicity; dichloroacetate; glycolysis; platinum.

Figures

Figure 1
Figure 1
Sensitization of DMS 153 SCLC cells by either combined treatment with DCA 10 mM and platinum drugs or following pretreatment of cells with DCA 10 mM (mean ± standard deviation). For combined treatment, all ratios show significant effects, except for cisplatin and picoplatin; for pretreatment, all ratios show significant effects, except for JM118 and etoposide.
Figure 2
Figure 2
Effects of DCA 10 mM on cytotoxicity of cisplatin and satraplatin against ES-2 ovarian cancer cells (survival in percentage of control, mean ± standard deviation).

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med. 2010;31:60–74. - PubMed
    1. van der Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029–1033. - PMC - PubMed
    1. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989–994. - PMC - PubMed
    1. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37–51. - PubMed
    1. Wong JY, Huggins GS, Debidda M, et al. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008;109:394–402. - PMC - PubMed

LinkOut - more resources

Feedback